Nexgel (NXGL) Cash & Equivalents (2019 - 2025)

Nexgel has reported Cash & Equivalents for 7 years, with the latest figure at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 41.45% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 million (down 41.45% YoY), and the FY2025 full-year result was $1.1 million, down 41.45% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $1.1 million, up from $938000.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $13.4 million in Q4 2021, with the low at $382000.0 in Q2 2021.
• Historically, Cash & Equivalents has averaged $2.7 million across 5 years, with a median of $1.2 million in 2021.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 41618.75% — and 2023, when it plunged 92.52%.
• Nexgel's Cash & Equivalents stood at $13.4 million in 2021, then slumped by 91.75% to $1.1 million in 2022, then surged by 145.23% to $2.7 million in 2023, then slumped by 33.07% to $1.8 million in 2024, then plunged by 41.45% to $1.1 million in 2025.
• The last three Cash & Equivalents figures came in at $1.1 million (Q4 2025), $938000.0 (Q3 2025), and $725000.0 (Q2 2025), per Business Quant data.